SCHEMBL2549152

SCHEMBL2549152

COC(=O)CCc1ccc(OCCN(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.64
PPARG P37231 1/20 0.58
LTA4H P09960 3/20 0.56
KEAP1 Q14145 1/20 0.54
NFE2L2 Q16236 1/20 0.54
ESRRB O95718 1/20 0.54
HDAC3 O15379 1/20 0.53
ESR1 P03372 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
ADRB2 P07550 1/20 0.52
ADRB1 P08588 1/20 0.52
DRD2 P14416 2/20 0.50
DRD3 P35462 2/20 0.50
LMNA P02545 2/20 0.50
ACHE P22303 1/20 0.50
SLC6A2 P23975 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873847 0.85 HRH3 (0.68) HRH3LTA4HKEAP1NFE2L2HDAC3
SCHEMBL16689220 0.85 LMNA (0.69) HRH3PPARGLTA4HKEAP1NFE2L2
SCHEMBL12315757 0.85 ALDH1A1 (0.67) HRH3LTA4HKEAP1NFE2L2ESRRB
SCHEMBL8134234 0.83 CHRNB2 (0.54) PPARGLTA4HESRRBALDH1A1LMNA
SCHEMBL7528179 0.83 LMNA (0.62) HDAC6SMN1; SMN2ALDH1A1ADRB2ADRB1
SCHEMBL7631798 0.82 LTA4H (0.63) PPARGLTA4HLMNAKCNH2L3MBTL1
SCHEMBL1495266 0.82 ADRB2 (0.54) PPARGLTA4HALDH1A1ADRB2ADRB1
SCHEMBL28549048 0.82 ADRB2 (0.54) PPARGLTA4HALDH1A1ADRB2ADRB1
SCHEMBL13932451 0.82 FFAR1 (0.60) PPARGLTA4HADRB2ADRB1LMNA
SCHEMBL28543599 0.82 ADRB2 (0.54) PPARGLTA4HADRB2ADRB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2555623-A1 FLAVIN DERIVATIVES BioRelix, Inc. (US) 2013-02-13 EP disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
WO-2011126567-A1 FLAVIN DERIVATIVES BIORELIX, INC. (US) 2011-10-13 WO disclosed
WO-2011126567-A1 FLAVIN DERIVATIVES BIORELIX, INC. (US) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029980-A1 FLAVIN DERIVATIVES BLVRB, FLAD1, FDPS HRH3 4388/4885PPARG 1119/4885LTA4H 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.